Tara C. Gangadhar
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer(2015)2,368 cited
- → Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial(2014)1,753 cited
- → T-cell invigoration to tumour burden ratio associated with anti-PD-1 response(2017)1,620 cited
- → Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial(2015)1,554 cited
- → Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade(2016)1,126 cited
- → Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma(2016)1,053 cited
- → Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab(2016)741 cited
- → Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma(2016)667 cited
- → Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma(2017)478 cited